Advertisement

DNase-I functionalization of ciprofloxacin-loaded chitosan nanoparticles overcomes the biofilm-mediated resistance of Pseudomonas aeruginosa

  • Krishna Kumar Patel
  • Ashish Kumar AgrawalEmail author
  • Md. Meraj Anjum
  • Muktanand Tripathi
  • Nidhi Pandey
  • Sankha Bhattacharya
  • Ragini Tilak
  • Sanjay SinghEmail author
Original Article
  • 13 Downloads

Abstract

Pseudomonas aeruginosa infection in cystic fibrosis (CF) is a major complication which aggravates the disease complexity and progression. The improvement of antimicrobial therapy against the P. aeruginosa biofilm infection in CF by dissembling the extracellular matrix is a fundamental concept of this study. Chitosan nanoparticle was successfully fabricated and characterized. Furthermore, various in vitro antimicrobial efficacy, biofilm dispersal potential, and in vitro as well as in vivo toxicity were assessed. The chitosan nanoparticles of ciprofloxacin functionalized with DNase-I had spherical shape with desired quality attributes (particle size—212.3 ± 8.9; polydispersity index—0.288 ± 0.06, zeta potential—14.6 ± 1.3, and entrapment efficiency—53.7 ± 3.8%). The developed DNase-I functionalized chitosan nanoparticles laden with ciprofloxacin demonstrated substantial and prolonged microbial inhibition, efficiently prevented the biofilm development, and possessed the excellent biofilm dispersal potential. Moreover, the confocal study demonstrated that the biofilm treated with DNase-I functionalized chitosan nanoparticles of ciprofloxacin had minimum biofilm thickness, biomass, and microbial density compared to the other treatment groups. Additionally, the developed formulation was found to be safe and had minimal in vitro as well as in vivo toxicity. Thus, the findings of this study suggests ciprofloxacin-loaded chitosan nanoparticles functionalized with DNase-I as an effective and safe treatment approach for the P. aeruginosa infection in CF.

Keywords

Chitosan nanoparticles DNase-I Cystic fibrosis Ciprofloxacin Biofilm 

Notes

Acknowledgements

The authors are grateful to Indian Institute of Technology (Banaras Hindu University), Varanasi, for rendering the support in terms of infrastructure, facilities, and research support grant to complete the work on time. We also thank the Central Instrument Facility Centre, IIT (BHU), Varanasi for extending the facilities when needed. We also acknowledge the Interdisciplinary school of life sciences, Institute of Science, Banaras Hindu University, Varanasi for confocal microscopy. Moreover, we are also thankful to Ministry of Human Resources and Development, Government of India for offering Mr. K.K. Patel teaching assistantship to complete his Ph.D.

Compliance with ethical standards

Conflict of interest

Authors have no conflict of interest.

References

  1. Agrawal AK, Harde H, Thanki K, Jain S (2013) Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromol 15(1):350–360CrossRefGoogle Scholar
  2. Agrawal AK, Urimi D, Harde H, Kushwah V, Jain S (2015) Folate appended chitosan nanoparticles augment the stability, bioavailability and efficacy of insulin in diabetic rats following oral administration. RSC Adv 5(127):105179–105193CrossRefGoogle Scholar
  3. Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, Alhakeem SS, Oben K, Munagala R, Bondada S (2017a) Milk-derived exosomes for oral delivery of paclitaxel. Nanomed Nanotechnol Biol Med 13(5):1627–1636CrossRefGoogle Scholar
  4. Agrawal AK, Kumar K, Swarnakar NK, Kushwah V, Jain S (2017b) “Liquid crystalline nanoparticles”: rationally designed vehicle to improve stability and therapeutic efficacy of insulin following oral administration. Mol Pharm 14(6):1874–1882CrossRefGoogle Scholar
  5. Algburi A, Comito N, Kashtanov D, Dicks LMT, Chikindas ML (2017) Control of biofilm formation: antibiotics and beyond. Appl Environ Microbiol 83(3):e02508–e02516CrossRefGoogle Scholar
  6. Alipour M, Suntres ZE, Omri A (2009) Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 64(2):317–325CrossRefGoogle Scholar
  7. Al-Nemrawi N, Alshraiedeh NA, Zayed A, Altaani B (2018) Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharmaceuticals 11(1):28CrossRefGoogle Scholar
  8. Aqil F, Munagala R, Jeyabalan J, Agrawal AK, Gupta R (2017) Exosomes for the enhanced tissue bioavailability and efficacy of curcumin. AAPS J 19(6):1691–1702CrossRefGoogle Scholar
  9. Baelo A, Levato R, Julián E, Crespo A, Astola J, Gavaldà J, Engel E, Mateos-Timoneda MA, Torrents E (2015) Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. J Control Release 209:150–158CrossRefGoogle Scholar
  10. Bilati U, Allémann E, Doelker E (2005) Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 24(1):67–75CrossRefGoogle Scholar
  11. Cheow WS, Chang MW, Hadinoto K (2010) Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm Res 27(8):1597–1609CrossRefGoogle Scholar
  12. Chiang W-C, Nilsson M, Jensen PØ, Høiby N, Nielsen TE, Givskov M, Tolker-Nielsen T (2013) Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 57(5):2352–2361CrossRefGoogle Scholar
  13. Cutting K, Percival S, Williams D (2009) Biofilms: possible strategies for suppression in chronic wounds. Nurs Stand 23(32):64–72Google Scholar
  14. Del Pozo J, Patel R (2007) The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther 82(2):204–209CrossRefGoogle Scholar
  15. Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K (2014) Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release 190:607–623CrossRefGoogle Scholar
  16. Harde H, Agrawal AK, Jain S (2014) Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine 9(16):2511–2529CrossRefGoogle Scholar
  17. Hou J, Yu X, Shen Y, Shi Y, Su C, Zhao L (2017) Triphenyl phosphine-functionalized chitosan nanoparticles enhanced antitumor efficiency through targeted delivery of doxorubicin to mitochondria. Nanoscale Res Lett 12(1):158CrossRefGoogle Scholar
  18. Jain S, Patil SR, Swarnakar NK, Agrawal AK (2012) Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharm 9(9):2626–2635CrossRefGoogle Scholar
  19. Jain S, Spandana G, Agrawal AK, Kushwah V, Thanki K (2015) Enhanced antitumor efficacy and reduced toxicity of docetaxel loaded estradiol functionalized stealth polymeric nanoparticles. Mol Pharm 12(11):3871–3884CrossRefGoogle Scholar
  20. Jørgensen KM, Wassermann T, Jensen PØ, Hengzuang W, Molin S, Høiby N, Ciofu O (2013) Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother 57(9):4215–4221CrossRefGoogle Scholar
  21. Juárez-Morales L, Hernandez-Cocoletzi H, Chigo-Anota E, Aguila-Almanza E, Tenorio-Arvide M (2017) Chitosan-aflatoxins B1, M1 interaction: a computational approach. Curr Org Chem 21(28):2877–2883Google Scholar
  22. Kaplan JB, LoVetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, Izano EA (2012) Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot 65(2):73CrossRefGoogle Scholar
  23. Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR (2018) Defining antimicrobial resistance in cystic fibrosis. J Cystic Fibros.  https://doi.org/10.1016/j.jcf.2018.08.014 Google Scholar
  24. Kushwah V, Agrawal AK, Dora CP, Mallinson D, Lamprou DA, Gupta RC, Jain S (2017) Novel gemcitabine conjugated albumin nanoparticles: a potential strategy to enhance drug efficacy in pancreatic cancer treatment. Pharm Res 34(11):2295–2311CrossRefGoogle Scholar
  25. Kushwah V, Katiyar SS, Dora CP, Agrawal AK, Lamprou DA, Gupta RC, Jain S (2018) Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management. Acta Biomater 73:424–436CrossRefGoogle Scholar
  26. Mu H, Tang J, Liu Q, Sun C, Wang T, Duan J (2016) Potent antibacterial nanoparticles against biofilm and intracellular bacteria. Sci Rep 6:18877CrossRefGoogle Scholar
  27. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A (2007) Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 32(2):140–150CrossRefGoogle Scholar
  28. Okshevsky M, Regina VR, Meyer RL (2015) Extracellular DNA as a target for biofilm control. Curr Opin Biotechnol 33:73–80CrossRefGoogle Scholar
  29. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288(5469):1251–1253CrossRefGoogle Scholar
  30. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z (2019) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37(1):177–192CrossRefGoogle Scholar
  31. Patel KK, Gade S, Anjum MM, Singh SK, Maiti P, Agrawal AK, Singh S (2019a) Effect of penetration enhancers and amorphization on transdermal permeation flux of raloxifene-encapsulated solid lipid nanoparticles: an ex vivo study on human skin. Appl Nanosci.  https://doi.org/10.1007/s13204-019-01004-6 Google Scholar
  32. Patel KK, Surekha DB, Tripathi M, Anjum MM, Muthu M, Tilak R, Agrawal AK, Singh S (2019b) Anti-biofilm potential of silver sulfadiazine loaded nanoparticle formulations: a study on the role of DNase-I in microbial biofilm and wound healing activity. Mol Pharm.  https://doi.org/10.1021/acs.molpharmaceut.9b00527 Google Scholar
  33. Prochazkova S, Vårum KM, Ostgaard K (1999) Quantitative determination of chitosans by ninhydrin. Carbohyd Polym 38(2):115–122CrossRefGoogle Scholar
  34. Ramos MADS, Da Silva PB, Sposito L, De Toledo LG, Bonifacio BV, Rodero CF, Dos Santos KC, Chorilli M, Bauab TM (2018) Nanotechnology-based drug delivery systems for control of microbial biofilms: a review. Int J Nanomed 13:1179CrossRefGoogle Scholar
  35. Rybtke TM, Jensen PO, Hoiby N, Givskov M, Tolker-Nielsen T, Bjarnsholt T (2011) The implication of Pseudomonas aeruginosa biofilms in infections. Inflamm Allergy-Drug Targets (Formerly Curr Drug Targets Inflamm Allergy) 10(2):141–157Google Scholar
  36. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG (2002) Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 184(4):1140–1154CrossRefGoogle Scholar
  37. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME (1996) In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 51(2):119–125CrossRefGoogle Scholar
  38. Suk JS, Lai SK, Wang Y-Y, Ensign LM, Zeitlin PL, Boyle MP, Hanes J (2009) The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30(13):2591–2597CrossRefGoogle Scholar
  39. Tetz VV, Tetz GV (2010) Effect of extracellular DNA destruction by DNase I on characteristics of forming biofilms. DNA Cell Biol 29(8):399–405CrossRefGoogle Scholar
  40. Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ (2008) In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int J Antimicrob Agents 31(4):329–336CrossRefGoogle Scholar
  41. Urimi D, Agrawal AK, Kushwah V, Jain S (2019) Polyglutamic acid functionalization of chitosan nanoparticles enhances the therapeutic efficacy of insulin following oral administration. AAPS PharmSciTech 20(3):131CrossRefGoogle Scholar
  42. Van Acker H, Van Dijck P, Coenye T (2014) Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol 22(6):326–333CrossRefGoogle Scholar
  43. Wang L, Hu C, Shao L (2017) The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomed 12:1227CrossRefGoogle Scholar
  44. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS (2002) Extracellular DNA required for bacterial biofilm formation. Science 295(5559):1487CrossRefGoogle Scholar
  45. Wu H, Moser C, Wang H-Z, Høiby N, Song Z-J (2015) Strategies for combating bacterial biofilm infections. Int J Oral Sci 7(1):1CrossRefGoogle Scholar
  46. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y (2009) Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30(10):1947–1953CrossRefGoogle Scholar

Copyright information

© King Abdulaziz City for Science and Technology 2019

Authors and Affiliations

  • Krishna Kumar Patel
    • 1
  • Ashish Kumar Agrawal
    • 1
    Email author
  • Md. Meraj Anjum
    • 1
  • Muktanand Tripathi
    • 2
  • Nidhi Pandey
    • 2
  • Sankha Bhattacharya
    • 1
  • Ragini Tilak
    • 2
  • Sanjay Singh
    • 1
    Email author
  1. 1.Department of Pharmaceutical Engineering and TechnologyIndian Institute of Technology (IIT-BHU)VaranasiIndia
  2. 2.Department of Microbiology, Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations